Sprint Bioscience licenses the cancer drug program Vps34 to Deciphera Pharmaceuticals ...Middle East

PR Newswire - News
STOCKHOLM, Aug. 3, 2021 /PRNewswire/ -- Sprint Bioscience AB (publ) announces today that the company has licensed its cancer drug program Vps34 to the US pharmaceutical company Deciphera Pharmaceuticals. The license agreement covers exclusive global rights to the program. The agreement...

Read More Details
Finally We wish PressBee provided you with enough information of ( Sprint Bioscience licenses the cancer drug program Vps34 to Deciphera Pharmaceuticals )

Apple Storegoogle play

Also on site :

Most viewed in News